Treating asthma: is there a place for leukotriene receptor antagonists?

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma.

INTRODUCTION The prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics, and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve...

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma

Introduction The prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve ...

Role of leukotriene receptor antagonists in asthma.

Asthma is a chronic inflammatory disease that affects >300 million people worldwide. However, inhaled corticosteroids (ICS), the gold standard therapy for persistent asthma, cannot suppress every component of airway inflammation and often fail to adequately penetrate the small airways in order completely suppress eosinophilia. Cysteinyl leukotrienes are important inflammatory factors that are i...

Leukotriene receptor antagonists: useful in acute asthma?

Leukotriene receptor antagonists for the treatment of asthma.

Leukotriene receptor antagonists (LTRAs) are novel medications that provide symptom control in patients with persistent asthma. Current guidelines recommend the use of LTRAs as a treatment option for patients with mild-persistent asthma of at least 12 years of age. As illustrated by the results of controlled, multicenter clinical trials with zafirlukast and montelukast, as well as studies with ...